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Syncytiotrophoblast derived 
extracellular vesicles transfer 
functional placental miRNAs to 
primary human endothelial cells
Tina Cronqvist  1, Dionne Tannetta2, Matthias Mörgelin3, Mattias Belting4, Ian Sargent5, 
Mary Familari6 & Stefan R. Hansson1
During the pregnancy associated syndrome preeclampsia (PE), there is increased release of placental 
syncytiotrophoblast extracellular vesicles (STBEVs) and free foetal haemoglobin (HbF) into the 
maternal circulation. In the present study we investigated the uptake of normal and PE STBEVs by 
primary human coronary artery endothelial cells (HCAEC) and the effects of free HbF on this uptake. Our 
results show internalization of STBEVs into primary HCAEC, and transfer of placenta specific miRNAs 
from STBEVs into the endoplasmic reticulum and mitochondria of these recipient cells. Further, the 
transferred miRNAs were functional, causing a down regulation of specific target genes, including the 
PE associated gene fms related tyrosine kinase 1 (FLT1). When co-treating normal STBEVs with HbF, the 
miRNA deposition is altered from the mitochondria to the ER and the cell membrane becomes ruffled, 
as was also seen with PE STBEVs. These findings suggest that STBEVs may cause endothelial damage 
and contribute to the endothelial dysfunction typical for PE. The miRNA mediated effects on gene 
expression may contribute to the oxidative and endoplasmic reticulum stress described in PE, as well as 
endothelial reprogramming that may underlay the increased risk of cardiovascular disease reported for 
women with PE later in life.
Preeclampsia (PE) is a complex and severe pregnancy associated disorder and is diagnosed on the presence of 
newly developed hypertension and proteinuria from 20 weeks of gestation1. It is generally agreed that PE develops 
in two stages. During the first stage, the placenta is inadequately implanted which causes reduced placental per-
fusion, oxidative stress, increased placental apoptosis and excessive shedding of trophoblast debris. In the second 
stage, these components together with the anti-angiogenic factor, soluble receptor vascular endothelial growth 
factor (s-Flt), are released into the maternal circulation, where they cause systemic inflammation, endothelial dys-
function and organ failure2, 3. These factors, although not unique for PE, are present in excessive amounts during 
this disorder4, 5. Risk factors for PE include diabetes, obesity, previous PE pregnancies and chronic hypertension 
amongst others6.
Several placental factors have been suggested to link the first and second stage of PE. Studies from our research 
group suggest free foetal haemoglobin (HbF) may be an important factor in this transition7 as increased synthesis 
and accumulation of free HbF has been shown in PE placentas8. Further, leakage of HbF, from the damaged pla-
centa, into the maternal circulation has been demonstrated both ex vivo9 and in different cohort studies10, 11. The 
negative effects of free HbF and its metabolite heme on placental function have been confirmed in several animal 
studies12–14. By perfusing human normal placentae ex vivo with free Hb, an increased perfusion pressure and 
induction of PE-like pathological changes, as well as increased placental cell blebbing and formation of apoptotic 
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vesicles, was shown9, 15. Based on these studies, we hypothesized that free HbF may be responsible for inducing 
the increased shedding of syncytiotrophoblast extracellular vesicles (STBEVs) evident in PE16, 17.
Extracellular vesicles (EVs) are membrane vesicles released by all cells studied to date, and divided into 
exosomes and microvesicles based on size and site of formation in the cell. Exosomes are released by exocytosis 
from multivesicular bodies and have a size ranging between approximately 30–100 nm. Microvesicles are shed 
directly from the plasma membrane and range from 100nm-1µm in diameter. The placenta also releases syncytial 
nuclear aggregates (20–500 µm) as well as apoptotic bodies (1–4 µm)18, 19. Placental EVs are often referred to as 
STBEVs due to their syncytiotrophoblast cell of origin, and they are believed to play an important role both in 
normal and dysfunctional pregnancies. It has been suggested that STBEVs adapt the maternal immune system to 
the on-going normal pregnancy20, 21. In PE, the plasma level of STBEVs is increased and PE STBEVs show differ-
ent characteristics compared to normal STBEVs. For example, PE STBEVs show increased expression of Tissue 
Factor (TF)18, 22, which may trigger the immune system to be more active and/or damaging16, 17. It is also known 
that PE STBEVs are larger in size compared to normal STBEVs23. The STBEVs are believed to be one factor that 
causes the endothelial dysfunction seen in PE24.
STBEVs carry15, 25 and transfer miRNAs to recipient cells26–28. miRNAs are short non-coding RNAs, which 
affect gene expression either by degrading mRNA, or by inhibiting mRNA translation29. The chromosome 19 
miRNA cluster (C19MC) has been shown to be almost exclusively expressed in the placenta30–32 and C19MC 
miRNAs are found in placenta released STBEVs25, 26, 28, 33. C19MC miRNAs have been characterized in the mater-
nal circulation and their expression profile is altered in PE34, 35. We have reported that Hb perfusion of human 
placentas alter the miRNA content of released STBEVs from normal placentas15.
Several studies have shown increased arterial stiffness – an indicator of endothelial dysfunction, in women 
with PE – correlating with PE severity24. Women with PE have an increased risk of cardiovascular disease later 
in life, possibly due to PE-induced endothelial and vascular dysfunction36, 37. We hypothesize that the increased 
levels of STBEVs together with free HbF play an important role in endothelial dysfunction, by inducing oxida-
tive stress and membrane damage. We also hypothesize that STBEVs transfer potentially functional miRNAs, 
to endothelial cells to alter gene expression, leading to cellular alterations that cause long term changes in the 
endothelium. In the present study, we investigated the uptake of STBEVs, isolated from perfused placentas, from 
normal and PE pregnancies, by primary human coronary artery endothelial cells (HCAECs). To mimic the dou-
ble hit seen in PE, with altered STBEVs as well as increased HbF, the role of free HbF on the STBEV uptake was 
specifically studied. We also investigated the transfer of placental miRNAs and their effects on endothelial cell 
target gene expression.
Results
Characterisation of STBEVs. Nanoparticle Tracking Analysis. To determine vesicle count and size dis-
tributions of normal and PE STBEVs, we used the Nanoparticle Tracking Analysis (NTA) methodology. Mean 
vesicle sizes were 206 ± 20 nm and 195 ± 27 nm for normal and PE STBEVs respectively (Fig. 1a). No significant 
differences were observed in terms of vesicle count or size ranges between groups.
Figure 1. Characterisation of STBEVs using NTA and western blotting. Using Nanoparticle Tracking Analysis 
(NTA), vesicle size distribution and concentration was determined. The NTA showed STBEV vesicle sizes 
ranging between 50–500 nm (a) for both normal and PE STBEVs. Both normal and PE STBEV samples were 
PLAP positive by western blotting (b), shown by using the primary antibody NDOG2 against the STBEV 
surface marker PLAP (60 kDa). Each lane represents one individual sample. Blots have been cropped and 
inverted, see Supplementary Information S5 for full-length blots. Please note that the molecular marker shown 
in this figure is from a different blot run simultaneously, also shown in Supplementary Information S5.
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Western Blot. Western blot analysis showed that both normal and PE STBEV samples were PLAP positive, con-
sistent with their placental syncytiotrophoblast origin (Fig. 1b).
STBEV uptake in primary human coronary artery endothelial cells. Time course assessment of 
STBEV uptake. The uptake of PKH-labelled STBEVs in primary HCAECs was visualized by fluorescence 
microscopy (Fig. 2a) and quantified over time using flow cytometry (Fig. 2b). There was no obvious uptake after 
15 minutes incubation, but uptake was detected after 30 minutes and increased throughout the 24 hours time 
course. At 24 hours, all visualised cells appeared positive for PKH-stained STBEVs. There were no apparent dif-
ferences in uptake pattern between normal and PE derived STBEVs, with respect to time-course or number of 
PKH-STBEV positive cells.
Confocal microscopy. PKH-labelled STBEV internalization was confirmed by confocal microscopy, clearly 
showing that the STBEVs were not located on the cell surface (Fig. 3). The dynamics of internalized STBEVs 
could be further visualized by real-time confocal imaging (Supplementary information S1: video). Confocal 
imaging was more sensitive than flow cytometry analysis, and this analysis clearly demonstrates internalised 
STBEVs at 20 min. At 60 min of internalisation STBEVs were not as widely distributed in the cell cytoplasm, but 
appeared closer to the cell nucleus (Fig. 3).
Figure 2. Time course assessment of STBEV uptake. HCAEC uptake of PKH-labelled STBEVs was visualised 
using fluorescent microscopy (a). A representative image of HCAECs following 6 hours of incubation with 
PKH-labelled STBEVs. The cell nuclei are labelled blue and PKH-labelled STBEVs are seen as green. Time-
dependent uptake of normal (b, N1-N3) and PE (c, PE1-PE3) STBEVs was quantified using flow cytometry. 
Although variable between samples, all samples showed a time-dependent uptake. The horizontal axis shows 
mean fluorescent values; a.u., arbitrary units.
Figure 3. Live confocal microscopy visualizing STBEV uptake and intracellular transport. Uptake of PKH-
labelled STBEVs into HCAECs was followed by live confocal microscopy. Three representative cells are shown 
after 20 and 60 min of incubation. After 20 min the STBEVs are clearly internalised and widely distributed in 
the cell cytoplasm. After 60 min the STBEVs appear to be closer to the cell nuclei. Cell nuclei are pseudocolored 
in green, and PKH-labelled STBEVs in red. The figures are from live imaging, explaining the lower intensity at 
60 minutes due to bleaching.
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STBEV transfer of miRNAs to primary human coronary artery endothelial cells. Micro-RNA 
analysis. Total RNA was extracted from HCAEC cultures treated with normal or PE STBEVs. The miRNAs 
belonging to the C19 miRNA cluster (C19MC) and the 371–373 cluster, as well as four commonly expressed 
miRNAs (mir-210; mir-222; mir-16; mir-141*) were analysed using a custom TaqMan® miRNA array card from 
Applied Biosystems (The full list of miRNA sequences are listed in Supplementary information S2). The miRNAs 
showing expression levels at the cut-off value Ct <35 in all triplicates for one or more samples were included for 
further analysis. Out of the 52 C19MC miRNAs examined, 12 miRNAs fulfilled these criterion (marked with # 
in S2, Ct values presented in Supplementary information Table S3). Of special interest were the three C19MC 
miRNAs mir-517c, mir-517a and mir-519a, which were expressed in a majority of the samples but not in the 
controls, i.e. untreated cells. None of the 371–373-cluster miRNAs, fulfilled the cut-off criteria. Mir-210, mir-222 
and mir-16, were expressed in all samples including the controls. Mir-141* was not detected in any samples. In 
the array analysis, there was significantly lower expression of mir-210 in the PE STBEV treated cells compared 
to cells treated with STBEVs from normal pregnancies (p = 0.022, Table S3). The mir-222 showed significantly 
higher expression in the cells treated with normal STBEVs compared to the untreated control cells (p = 0.031, 
Table S3). These differences however could not be confirmed using real time quantitative PCR (RTqPCR). There 
was no significant difference between normal and PE STBEV treatments (Table S3). The endogenous control U6 
snRNA was stably expressed throughout all samples.
Based on the array results, four miRNAs (mir-517a, mir-517c, mir-519a and mir-210) were selected for fur-
ther analysis using RTqPCR. Control cells, i.e. not treated with STBEV, did not express these three C19MC miR-
NAs. The analysis confirmed the presence of the three C19MC miRNAs in cells treated with either normal or PE 
STBEVs (Fig. 4a). After treatment with normal STBEVs, the levels of mir-517a, mir-517c and mir-519a increased 
significantly (p = 0.00164, p = 0.0002 and p = 0.00164 respectively). Treatment with PE STBEVs also caused a sig-
nificant increase (p = 0.00124, p = 0.00012 and p = 0.00124 respectively). The mir-210 expression levels remained 
stable in the cells regardless of treatment group (Fig. 4b), most likely reflecting the cells endogenous mir-210 
expression. This also suggests that the STBEVs contain very low levels of mir-210, consistent with previous studies 
showing that trophoblast cells release vesicles mainly containing C19MC miRNAs25.
Micro-RNA target genes. The strategy for predicting miRNA targets is detailed in the Methods section. Briefly, 
by using three different prediction algorithms, as well as the TarBase database for experimentally validated 
miRNA targets, we identified putative target genes for the miRNAs mir-517a, mir-517c and mir-519a (Fig. 5). 
The following genes were analysed by RTqPCR; fms related tyrosine kinase (FLT1), transforming growth factor 
beta receptor 2 (TGFBR2), platelet derived growth factor D (PDGFD), very low density lipoprotein receptor 
(VLDLR), estrogen receptor 1 (ESR1) and programmed cell death 1 ligand 2 (PDCD1LG2). As an indicator of 
cell stress, heme oxygenase 1 (HMOX1) was analysed. The VLDLR mRNA expression remained unchanged after 
both normal (p > 0.05) and PE (p = 0.039, fold change <1.5) STBEV treatment. The ESR1 mRNA expression was 
not detectable in our samples. Normal STBEV treatment led to significant down regulation of the genes FLT1 
(p = 0.0014), TGFBR2 (p = 0.0074), PDGFD (p = 0.0074), PDCD1LG2 (p = 0.0033) and HMOX1 (p = 0.0096), 
In the same manner, PE STBEV treatment lead to significant down regulation of FLT1 (p = 0.0005), TGFBR2 
(p = 0.0021), PDGFD (p = 0.0012), PDCD1LG2 (p = 0.0012) and HMOX1 (p = 0.0071). There was no statistically 
significant difference comparing normal and PE STBEV treatment (Figs 4c and 5).
Transmission Electron Microscopy. STBEV characterisation. The placental marker PLAP was visual-
ized on vesicles of all sizes using Transmission Electron Microscopy (TEM) (Supplementary Figure S4). The 
estimated size range was 10–400 nm in both normal and PE (Supplementary Figure S4a) samples, which was 
in good agreement with the NTA data in Fig. 1a. By using a gold-labelled miRNA primer (hsa-mir-517c), mir-
517c could be visualized inside both PLAP positive and PLAP negative STBEVs, the PE STBEVs shown in 
Supplementary Figure S4b. Furthermore, mir-517c was also localized outside of the vesicles, in what appeared to 
be protein complexes. HbF was visualized with HbF specific antibodies inside both PLAP positive and PLAP neg-
ative PE STBEVs of all sizes (Supplementary Figure S4c). Normal STBEVs did not contain HbF (Supplementary 
Figure S4d).
Cell analysis. Uptake of STBEVs into HCAECs was visualized using TEM. The placental marker PLAP was 
located on vesicles outside the cells, bound to the cell surface, as well as inside the endothelial cells in different 
compartments (Fig. 6). The PLAP marker was also found to be recycled to the cell membrane (Fig. 6g). Both nor-
mal and PE STBEVs were positive for PLAP and mir-517c. The mir-517c remained co-localized with PLAP pos-
itive vesicles until the STBEVs reached the endosomes. Hereafter, the STBEVs appeared to be degraded, whereby 
PLAP was possibly recycled to the cell surface, and mir-517c re-located to either the endoplasmic reticulum (ER) 
or the mitochondria. The normal STBEVs appeared to deposit their miRNA content in higher quantity to the 
mitochondria (Fig. 6j, Table 1). In contrast, the PE STBEVs were deposited in a higher degree to the ER (Fig. 6e, 
Table 1). With TEM, the intracellular distribution could be followed, although it is worth mentioning that these 
results are primarily descriptive and not established statistically. Furthermore, treatment with PE STBEVs caused 
extensive damage to the endothelial cell membrane inducing membrane ruffling (Fig. 6b), which was not seen 
after treatment with normal STBEVs (Fig. 6g). The primary endothelial cells were also exposed to a combination 
of HbF and normal STBEVs (Fig. 6), to evaluate the potential role of the HbF found in the PE STBEVs. A severe 
membrane ruffling occurred (Fig. 7b and c), similar to that seen in cells treated with PE STBEVs. The normal 
STBEVs were taken up into endosomes (Fig. 7d), but the co-treatment with HbF resulted in miRNA deposition 
shifting towards the ER (Fig. 7e and f), as was seen for PE STBEVs.
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Discussion
The present study provides evidence that STBEVs are internalized into HCAECs, and that STBEV cargo, placenta 
specific miRNAs, is transferred into recipient cells. To our knowledge, no previous uptake studies have been 
performed on HCAECs using STBEVs from perfused placentas. Previous studies have visualized the uptake of 
mechanically derived placental or cell-culture derived syncytiotrophoblast vesicles into cells such as vascular 
smooth muscle cells38, BeWo cells or primary villous cytotrophoblasts39.
Figure 4. Micro-RNA and target gene expression in primary human coronary artery endothelial cells following 
STBEV treatment. The three placental C19MC miRNAs, mir-517a (a), mir-517c (b) and mir-519a (c), were 
analysed using RTqPCR. None of the three C19MC miRNAs were present in un-treated control cells. After 
treatment with normal (n = 5) or PE (n = 5) STBEVs, the levels of all three miRNAs increased significantly 
compared to control cells. No significant difference was seen in miRNA expression when comparing normal 
and PE STBEV treatments for any of the three C19MC miRNAs. The mir-210 (d) was present in controls cells 
and unaffected by STBEV treatment. The miRNA expression is expressed as fold change (±SD), which were 
calculated by normalizing against cells treated with normal STBEVs. Expression level of the predicted target 
gene FLT1 (e) was down regulated after normal (n = 5) and PE (n = 5) STBEV treatment. FLT1 is shown here 
as representative of the four genes; FLT1, TGFBR2, PDGFD and PDCD1LG2, all affected similarly by STBEV 
treatment. See also Fig. 5. The expression of predicted target genes was calculated as fold change (±SD) by 
normalizing against control samples, i.e. untreated control cells. Differences between control and normal 
STBEV treatments, as well as between control and PE STBEV groups, were analysed using Mann-Whitney U-
test. *p < 0.05, **p < 0.01, ***p < 0.001.
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The results show that STBEVs are internalized with increased uptake after longer incubation time, lending 
support to the notion that uptake of STBEVs into HCAECs is active and involves a specific uptake mechanism. 
The evidence for STBEV internalization was obtained both indirectly by flow cytometry, as well as directly 
by confocal microscopy live imaging and TEM. The flow cytometry analysis was also used to quantify the 
time-dependent uptake observed in vitro. In our hands, the STBEV uptake was significant after 15–30 minutes, 
with increasing uptake throughout the 24-hour time course. Prior to internalization, the STBEVs appeared to 
bind to the cell surface. Using TEM, we showed that the STBEVs were transported to endosomes, where it is pos-
sible that the vesicles were degraded and re-cycled to the cell-surface, as appears to be the case for PLAP labelled 
vesicles. The uptake into endosomes suggests that the STBEVs are, at least in part, taken up by endocytosis, but 
the presence of PLAP on the plasma membrane, could also suggest a partial uptake through membrane fusion. 
The exact uptake mechanisms and whether these differ between EV subgroups of exosomes and microvesicles, 
remains to be elucidated18.
The miRNA content (specifically mir-517c) was, after vesicle degradation, transported primarily to the rough 
endoplasmic reticulum (ER) or the mitochondria. Localization of miRNAs to the ER suggests that the miRNAs 
are actively involved in regulating gene expression at the translational level. Data on target gene expression fur-
ther supports the idea that STBEV miRNAs are functional after uptake, since several C19MC miRNA predicted 
or validated target genes were down regulated. Previous studies have also shown vesicles affecting target gene 
expression in recipient cells. For example, human umbilical vein endothelial cells (HUVECs) were shown to 
take up plasma-EVs derived from pregnant women, and several studies have reported that STBEV had effects on 
both gene expression and cellular functions40–42. In addition there were different effects depending on whether 
the EVs were derived from normal or PE patients43. In the present study we saw no difference in target gene 
down-regulation when comparing normal and PE STBEVs. The miRNA expression data suggests that normal and 
PE STBEVs contain the same amount of C19MC miRNAs, and the cells were treated with equivalent concentra-
tions of STBEVs, which could explain why the effect on gene expression is similar. Another possible explanation is 
Figure 5. Target gene fold changes in HCAECs, after treatment with normal or PE STBEVs compared to 
controls. Heat-map showing fold change for each gene relative to control cells. A deviation from 1.0 indicates 
down-regulation of gene expression. N.D (not detected) in HCAEC cells.
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Figure 6. STBEV uptake and miRNA transfer visualised by transmission electron microscopy. By using TEM, 
PE STBEVs (a–e) and normal STBEVs (f–j) were visualized in HCAECs. In panel (a), PE STBEVs approach the 
HCAEC. In (b) and (c), PE STBEV appears to be binding to the ruffled plasma membrane. The STBEV is seen 
inside the cells in what appears to be an endosome (d), in close proximity to the mitochondria, endoplasmic 
reticulum and cell nucleus. The mir-517c from PE STBEVs appears to be in larger number in the ER (e) 
compared to the mitochondria. PLAP appears to stay in the endosomes and is possibly recycled to the cell 
membrane. The normal STBEVs, which also carry mir-517c are found outside the cells (f–g) and can be found 
in endosomes (h,j). In contrast to PE STBEVs, mir-517c from normal STBEVs are localized in a higher degree 
to mitochondria and in lower quantity to the ER (j). The STBEV and miRNA intracellular distribution are also 
described in Table 1. Abbreviations; E endosome, ER endoplasmic reticulum, MV microvilli, M mitochondria, 
N nucleus, PM plasma membrane. PLAP labelled with 20 nm and mir-517c labelled with 5 nm colloidal gold.
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Normal STBEVs 
(n = 100)
PE STBEVs 
(n = 100)
Normal STBEVs+HbF 
(n = 100)
Plasma membrane 43 ± 10 69 ± 15 81 ± 18
Cytoplasm 39 ± 11 34 ± 12 36 ± 11
Endosomes 54 ± 9 66 ± 13 71 ± 12
Mitochondria 42 ± 6 28 ± 8 31 ± 10
ER 21 ± 4 39 ± 8 41 ± 9
Table 1. Semi-quantification of miRNA gold label per square micrometre in Transmission Electron Microscopy 
data.
Figure 7. STBEV uptake and effect of free HbF visualised by transmission electron microscopy. The normal 
STBEVs, co-treated with HbF, appear to bind the plasma membrane (a), which is ruffled (b,c) as was also 
seen in cells treated with PE STBEVs (see Fig. 6b). The STBEVs were internalised into endosomes (d) and 
transported to intracellular compartments (e,f). The mir-517c is localised predominantly into the ER than in 
the mitochondria (e,f), also seen in cells treated with PE STBEVs (see Fig. 6e). Abbreviations; E endosome, ER 
endoplasmic reticulum, MV microvilli, M mitochondria, N nucleus, PM plasma membrane. PLAP labelled with 
20 nm and mir-517c labelled with 5 nm colloidal gold.
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that there could be long-term effects after several months’ treatment, as is the case in pregnant women. The ruffled 
plasma membrane caused by PE STBEVs may lead to cellular dysfunction over time.
Interestingly, by semi-quantifying the gold labelled STBEVs with TEM, we saw that normal STBEV miR-
NAs were deposited at a higher degree in the mitochondria, while PE STBEV miRNAs primarily were depos-
ited to the ER. We speculate that this could be due to different molecules or tags on the EV surface, directing 
the intra-cellular transport of vesicles to different subcellular compartments. In previous studies, HbF has been 
shown to affect both mitochondria and ER14 and PE placentas are subject to high levels of both oxidative and ER 
stress44.
This led us to the hypothesis that the HbF inside PE STBEVs cause oxidative stress and damage to the mito-
chondria or ER, thereby re-directing the STBEVs and their miRNA cargo. The extensive membrane ruffling, seen 
after treatment with PE STBEVs as well as with normal STBEVs co-treated with free HbF, suggests destruction 
of the cytoskeleton, which also disrupts intracellular pathways. A functioning cytoskeleton is required for EV 
uptake through endocytosis45. The re-direction of STBEV cargo and shifted balance of STBEV miRNA deposition 
from the mitochondria to the ER could increase the ER stress further. This could possibly affect the translation 
of various proteins important for normal pregnancy adaptation. As shown here, even normal STBEVs transfer 
unique information in the form of placenta specific miRNAs. And this may be important for placenta-maternal 
communication.
Our TEM studies showed that PE STBEVs carried HbF. Since free HbF is a toxic molecule3 this could have 
damaging effects on endothelial cell structure and function, and may play an important role in causing the 
endothelial dysfunction characteristic of PE4. By co-treating normal STBEVs with HbF, similar cell membrane 
ruffling was seen, as with PE STBEVs alone, lending support to the notion that HbF is at least one of the harmful 
differences between normal and PE STBEVs. Various conditions have previously been shown to affect different 
EV uptake pathways. For example, blocking specific receptors with heparin or Annexin-V, inhibits endocytic 
uptake via protein-protein interactions. Further, acidic conditions increase uptake through membrane fusion, 
whereas low temperature (4 °C) inhibits the energy-requiring uptake through endocytosis45. We speculate that 
HbF may enhance or inhibit certain uptake pathways or intra-cellular transport mechanisms, for example by 
disrupting the cytoskeleton or inducing oxidative stress.
Regarding STBEV characterisation, the NTA data showed no difference in vesicle count or size distribution, 
between normal and PE samples. It is well documented that STBEVs increase significantly in the plasma of 
women with PE22. However, at present it is not possible to normalize the surface area of a perfused placenta, and 
generally only one cotyledon is perfused, and these vary in size even within a single placenta. Therefore the num-
ber of STBEV released per perfused cotyledon is variable. Further, the vesicle size can be affected by freezing46, 
which may explain the differences between the groups. We therefore draw no conclusions in this study regarding 
the STBEV count in plasma from pregnant women.
In conclusion, the results show STBEV uptake and internalization by HCAECs, and transfer of placenta 
specific miRNAs, which in turn affect predicted and validated target gene expression. Normal and PE STBEVs 
deposited their miRNA content in different cellular compartments and co-treatment with free HbF and normal 
STBEVs, re-directed the miRNA deposition to a pattern similar to that seen in cells treated with PE STBEVs. 
Also, PE STBEVs caused extensive cell membrane damage, not seen with normal STBEVs. In PE, there is a higher 
plasma concentration of both STBEVs and free HbF, which may lead to re-programming of endothelial cells that 
may cause detrimental cellular functions such as arterial stiffness24. This may explain the long-term cardiovascu-
lar consequences seen in women who have suffered PE during pregnancy37.
Methods
Ethics statement. The perfusion studies were approved by the Oxfordshire Research Ethics Committee C 
at Oxford University, and informed written consent was obtained from all participants. All experiments were 
performed in accordance with relevant guidelines and regulations.
Placental perfusion and sample collection. Dual ex-vivo perfusion of isolated human placental cot-
yledons from normal (n = 5) and PE (n = 5) pregnancies was performed as previously described47. Briefly, the 
perfusion experiment consisted of one equilibration phase of 30 minutes, from which the maternal perfusate was 
discarded. After equilibration, the maternal circuit was closed and the placenta was perfused for 3 hours. Only 
perfusions with a foetal return rate of >80% were included. The perfusate was collected from the maternal side at 
the end of the 3 hours perfusion and used for isolation and analysis of STBEVs. The placental perfusion method 
was chosen for collecting normal and PE STBEVs in this study, due to the large vesicle yield that is available using 
this method, and the possibility to study STBEVs from syncytiotrophoblasts in PE placentas48.
Isolation of STBEVs. The STBEV isolation was performed using sequential centrifugation steps. After per-
fusion, the maternal perfusate was centrifuged at 600 × g or 1500 × g to remove red blood cells, and the superna-
tant was frozen at −80 °C until further analysis. The supernatant was centrifuged for 30 minutes at 3,500 × g and 
4 °C to remove cellular debris. The 3,500 × g supernatant was further ultra-centrifuged for 3 hours at 110,000 × g 
at 4 °C, and the pelleted material used for further study and referred to as the STBEVs. The STBEV protein 
concentrations were determined using a NanoDrop Spectrophotometer ND-1000 (NanoDrop Technologies, 
Wilmington, USA), or using the Pierce™ BCA Protein Assay (Thermo Scientific, Rockford, USA). The STBEVs 
were re-suspended in 1xPhosphate Buffered Saline (PBS), and stored at −80 °C.
STBEV characterisation using Nanoparticle Tracking Analysis. For quantification and determi-
nation of size distribution, the STBEVs were analysed using NTA, with the NanoSight LM10 (Nanosight Ltd., 
Amesbury, UK) equipped with 635 nm laser. The STBEV preparations from normal (n = 5) and PE (n = 5) 
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placentas, isolated by ultra centrifugation, were immediately diluted 1:1000 in 1xPBS and frozen at −80 °C until 
analysis. The diluted samples was introduced into the sample chamber at room temperature (22.7 ± 0.23 °C) using 
1 mL syringes, and the chamber was washed between samples with PBS. For each sample, a 30-second video was 
recorded, using a camera gain of 400. The video was analysed using the NTA 2.3 software (NTA 2.3 build 0356 
from Nanosight Ltd). Camera level was set to 14 and detection threshold set to 10. Automatic settings were used 
for all other parameters.
STBEV characterisation using Western Blot. For identification of the STBEV surface marker placental 
alkaline phosphatase (PLAP), western blotting was carried out on STBEV lysates. Briefly, 10ug/well per sample of 
total protein from normal STBEVs (n = 2) and PE STBEVs (n = 2) were separated on 4–20% bis-tris gradient gel 
(Bio-Rad, Hercules, CA, USA), using molecular weight standard (Precision Plus All Blue, Bio-Rad). Separated 
proteins were transferred onto PVDF membranes, and nonspecific binding blocked with 5% Blotting-Grade 
Blocker (Nonfat Dry Milk, Bio-Rad) in PBS-Tween. The membranes were incubated with the primary anti-
body NDOG2 against PLAP (made in-house and provided by Prof Sargent) overnight at 4 °C. Membranes were 
washed prior to incubation with the secondary antibody Alexa Fluor 647 goat anti-mouse IgG (Life Technologies, 
Carlsbad, CA, USA), washed again and thereafter the bands were detected in a ChemiDoc XRS unit (Bio-Rad).
Cell culture. Human coronary artery endothelial cells (HCAECs, Lonza Walkersville, Inc., MD, USA) 
were cultured in endothelial cell basal medium-2 supplemented with human epidermal growth factor (hEGF), 
hydrocortisone, human recombinant fibroblast growth factor-beta (hFGF-b), vascular endothelial growth fac-
tor (VEGF), insulin-like growth factor (R3-IGF-1), ascorbic acid, fetal bovine serum (FBS) and gentamicin/
amphotericin-B (GA). The cells were cultured in a humidified incubator with a gas supply of air and 5% CO2 at 
37 °C.
STBEV uptake in primary human coronary artery endothelial cells. Fluorescent labelling of 
STBEVs. Using the PKH67 Fluorescent Cell Linker Kit (Sigma-Aldrich, St. Louis, MO, USA), the STBEV mem-
branes were labelled with PKH67 dye according to manufacturer’s instructions. Briefly, the STBEV sample was 
mixed with diluent C and dye for 5–10 minutes, and the reaction stopped by adding FBS. For the initial time 
course assessment, using conventional fluorescence microscopy, the dyed STBEVs were recovered by centrifug-
ing the solution for 30 minutes at 20,000 × g, the pellet washed once with 1xPBS and repeating the centrifugation 
step for an additional 30 minutes. The final pellet was resuspended in 1xPBS. For confocal microscopy and flow 
cytometry analysis, the dyed STBEVs were washed and recovered by centrifuging for 3 hours at 100,000 × g twice 
before resuspension in 1xPBS.
Time course assessment using fluorescence microscopy. The HCAECs were plated on gelatine (1%) coated cover 
slips and incubated overnight. The following day, the medium was changed and PKH-labelled STBEVs (20ug/mL) 
added to the cultured cells, or vehicle only for controls (no STBEV treatment). The experiment was ended at spe-
cific time points; 15 minutes, 30, 45, 60, 90 and 120 minutes, and 6 or 24 hours. The media was removed and 2 mL 
Hoechst 33342 (1 µg/mL, Life Technologies), nuclear stain diluted in 1xPBS, was added for 5 minutes. The cells 
were washed with 1xPBS before adding 2 mL 4% paraformaldehyde (PFA) (HistoLab Products AB, Gothenburg, 
Sweden) for 10 minutes. The cells were once again washed with 1xPBS, the cover slips removed, tapped dry and 
mounted on to a microscope slide using FluoromountTM Aqueous Mounting Medium (Sigma-Aldrich). The cells 
were visualized using a Zeiss Axiostar plus microscope at 100x and 400x magnification.
Time course assessment using flow cytometry. The HCAECs were plated out in 24 well plates overnight, and the 
following day, treated with PKH-labelled normal (n = 3) or PE (n = 3) STBEVs (5ug/mL) in serum free medium 
for 30 minutes, 2 hours or 4 hours. All samples were analysed in duplicates or triplicates. Cells were detached by 
trypsinization and washed and resuspended in PBS before cell-associated fluorescence was measured using an 
Accuri C6 Flow cytometer and analysed using Accuri C6 software (BD Biosciences).
Confocal microscopy. To confirm the uptake and internalization of STBEVs into HCAECs, live cell confocal laser 
scanning microscopy was performed following treatment with normal or PE STBEVs. Cells were grown in glass 
bottom chamber slides, and 10–20 μg/ml of PKH-labeled STBEVs added to subconfluent cells in phenol red-free 
and serum-free conditions and incubated for 1 hour. Surface-bound STBEVs were removed by extensive washing 
with 1 M NaCl and serum-free medium, followed by live cell imaging of intracellular STBEV in phenol-red free 
medium. The acquisition of images was performed using Zeiss LSM 710 confocal scanning microscope equipped 
with excitation laser wavelengths of 405, 488, and 633 nm, and a C-Apochromat 63X/1.20 W korr M27 water or 
Plan-Apochromat 63X/1.40 DIC M27 oil immersion objective. Images were acquired using Zen 2011 software 
(Carl Zeiss). For live imaging, cells were transferred to a humidified 5% CO2, 21% O2 atmosphere incubator 
integrated with the confocal scanning equipment. Images were collected during a time series of approximately 
10 min with 10 s cycle time.
STBEV transfer of miRNAs to primary human coronary artery endothelial cells. Cell treat-
ment. The HCAECs were seeded into 6 well plates at a concentration of 0.2 × 106 cells per well. After reaching 
80% confluency, media was changed and normal (n = 5) or PE (n = 5) STBEVs added (20ug/mL). After 6 hours 
incubation, medium was removed and the cells washed with 1xPBS before addition of lysis buffer. The lysate was 
transferred to eppendorf tubes and frozen at −80 °C. As controls (n = 6), PBS or no vehicle/treatment were used.
RNA extraction and quality assessment. Total RNA was extracted using mirVana™ miRNA Isolation Kit 
(Applied Biosystems, Foster City, CA, USA) according to manufacturer’s instruction. RNA quality and miRNA 
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content was assessed with an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA) using the Nano 
Assay to evaluate RNA integrity number (RIN) value and total RNA quality, as well as the Small RNA Assay 
to investigate miRNA percentage and quality. A RIN value of 10 corresponds to intact RNA, and 1 to totally 
degraded RNA. The analysis confirmed the presence of high quality miRNA and RNA, which showed RIN values 
above 8.3 in all samples.
Profiling of placental miRNAs using a custom made miRNA array. To investigate the transfer of miRNAs from 
placental STBEVs, we designed a custom miRNA TaqMan® miRNA array card (Applied Biosystems). See 
Supplementary information Table S2, for a complete list of mature miRNA sequences from chromosome 19 
miRNA cluster (C19MC). The cluster gives rise to 52 individual mature miRNAs accoding to the miRBase.org 
database. The 371–373 cluster gives rise to 8 individual mature miRNAs. Included on the array were also four 
well known miRNAs, which are widely expressed and relevant in placenta research; hsa-miR-141*, hsa-miR-210, 
hsa-miR-1649 and hsa-miR-22250.
Using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems), total RNA was transcribed 
to cDNA according to manufacturer’s instructions. The cDNA was mixed with TaqMan® Universal PCR Master 
Mix before addition to the array cards. The custom miRNA TaqMan® miRNA array cards were of format 64, 
which included 63 target assays (described above) and one endogenous control (U6 snRNA). Each card ana-
lysed two unique samples. qPCR was performed using standard protocol supplied by manufacturer for TaqMan® 
Array Micro Fluidic Cards on a QuantStudio 7 Flex (Applied Biosystems). Data were normalised to the endog-
enous control U6 snRNA. Using the Thermo Fisher Cloud software (Thermo Fisher Scientific, 81 Wyman Street 
Waltham, MA USA 02451), the Comparative CT Method (ΔΔ CT Method, Applied Biosystems) was used, 
according to manufacturer’s instructions, to calculate fold differences relative to samples treated with normal 
STBEVs.
Real time quantitative PCR for miRNA analysis. Following miRNA array analysis, four miRNAs were selected 
based on changes in expression; mir-517c, mir-517a, mir-519a and mir-210. These specific miRNAs were verified 
and analysed with RTqPCR in cells treated with normal or PE STBEVs.
Total RNA was extracted using the mirVana™ miRNA Isolation Kit, as described above. Ten ng RNA was 
transcribed using TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems) according to manufac-
turer’s instructions. The following pre-designed TaqMan® MicroRNA assays (Applied Biosystems) were ana-
lysed: homo sapiens-microRNA-517c (hsa-mir-517c), hsa-mir-517a, hsa-mir-519a, hsa-mir-210 and U6 snRNA 
(sequences according to Supplementary information S2).
qPCR was performed using the standard protocol supplied by the manufacturer for TaqMan® MicroRNA 
Assays on an ABI PRISM 7000 sequence detection system (Applied Biosystems). Primers and probes were as 
described above. Each reaction was run in duplicate. Negative controls with no template as well as no reverse 
transcriptase controls were included for every miRNA primer pair. Data were normalized to U6 snRNA. Using 
the ΔΔCT method described by Livak et al.51, fold differences were calculated relative to samples treated with 
normal STBEVs for the C19MC miRNAs, since these miRNAs were not detected in control samples. However, for 
mir-210, fold differences were calculated relative to control cells, i.e. untreated cells, for mir-210. A p-value < 0.05 
was considered statistically significant. A fold change of >1.5 was defined as an increased miRNA content, while 
a fold change <1.5 was defined as a decrease.
Predicted miRNA target genes. Rationale. Current understanding of miRNA binding to target genes 
suggest that the 5′ end of the miRNA, via the seed sequence of 7–8 nucleotides is important and is conserved 
between species. Positions 1–10 are important for binding to Agonaute (Ago) in the RNA induced silencing 
complex (RISC) and bases 2–6 interact with mRNA. Binding to Ago requires a helical confirmation involving 
energy considerations. Another consideration is how much ‘imperfection’ in base-pairing can be tolerated in 
miRNA-mRNA interactions given that miRNA can bind to multiple places on one mRNA, and many differ-
ent miRNA can bind to one mRNA. The miRNA binding is considered to take place on the mRNA 3′ end but 
the coding region is also possible. Most computational prediction tools for miRNA target genes are considered 
to provide 30% precision52–54. All predicted targets need validation. Taking these considerations into account, 
the strategy used in this study was based on using predication models that focused on seed sequence stringent 
pairing, thermodynamic considerations, conserved seed sequences and where possible experimentally validated 
miRNA-mRNA interactions. Thus, the prediction programs chosen used multiple criteria. Unfortunately C19MC 
miRNA are primate-specific and therefore conservation criteria are limited, although TargetScan has Pan troglo-
dytes data. Target genes, if retrieved by several different computational prediction tools, were selected for further 
analysis via literature searching for interactions in the placenta or cardiovascular function.
Prediction algorithms. Using the prediction algorithms DIANA-microT-CDS (diana.imis.athena-innovation.
gr/DianaTools/index.php?r=microT_CDS/index)55, TargetScan (v7.0; targetscan.org)56 and miRmap (mirmap.
ezlab.org)57, we identified potential miRNA target genes for the C19MC miRNAs mir-517a, mir-517c and mir-
519a. By combining the gene lists from the three prediction algorithms, we found 33 genes for mir-517a and 
mir-517c as well as 872 genes for mir-519a. Using TarBase (v7.0; diana.imis.athena-innovation.gr/DianaTools/
index.php?r=tarbase/index)58, experimentally supported miRNA targets were identified. Tarbase provided one 
(1) experimentally supported gene for mir-517a, no genes for mir-517c and four (4) genes for mir-519a. The 
literature was searched for possible gene functions. The following genes: FLT1, TGFBR2, PDGFD, ESR1, VLDLR 
and PDCD1LG2 (Fig. 5), were selected for further analysis based on their algorithm prediction scores as well 
as being known to be involved in placental and/or cardiovascular function as well as PE. The gene expression 
levels were examined using RTqPCR. All genes, except FLT1, were predicted target genes by all three prediction 
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databases. FLT1 was chosen due to its significance in PE research as well as being a validated target for mir-517a/b 
and mir-517c59.
Real time quantitative PCR for target gene analysis. The HCAECs were, as described above, treated with nor-
mal or PE STBEVs. Total RNA was extracted, and transcribed using TaqMan® Reverse Transcription Reagents 
according to manufacturer’s instructions (Applied Biosystems). The following pre-designed qPCR assays (Applied 
Biosystems) were analysed: FLT1, TGFBR2, PDGFD, ESR1, VLDLR, PDCD1LG2, HMOX1, and GAPDH. 
RTqPCR was performed as described above.
Transmission Electron Microscopy. STBEV characterisation. The STBEVs were visualized and identi-
fied using TEM, as previously described60. Briefly, TEM was performed using the NDOG2 antibody against PLAP 
(made in-house and provided by Prof Sargent), the microRNA Assay primer hsa-mir-517c (Applied Biosystems 
Inc., Foster City, CA, USA) and an antibody against the human foetal Hb (HbF) protein. All antibodies and prim-
ers were labelled with colloidal gold (BBI International) of different sizes; NDOG2 (anti-PLAP, 20 nm), mir-517c 
primer (5 nm) and anti-HbF antibody (5 nm). The samples were processed for negative staining and sections 
were examined with a transmission electron microscope (CM100 Twin, Philips, Eindhoven, Holland) operated at 
a 60 kV accelerating voltage. The images were recorded with a side-mounted Olympus Veleta camera (Olympus, 
Münster, Germany).
Cell incubation with foetal haemoglobin. To evaluate the effect of free HbF on STBEV uptake and miRNA trans-
fer, HbF (0.7 mg/mL) was added to the cultured cells, with or without STBEVs. HbF was prepared from human 
cord blood and diluted in 15 mM Tris-HCl pH 8.0, 20 mM NaCl according to a previously published protocol14.
Cell analysis. For cell analysis, the HCAECs were incubated for 6 hours with normal or PE STBEVs, or normal 
STBEVs with HbF. Cells treated with 1xPBS only were used as controls. The TEM procedure was as described 
above. For a quantitative evaluation, 100 cellular profiles (n = 100) were analysed in each case from random dis-
tributions on different locations.
Statistical analysis. Statistical analysis was performed using Origin 9 software (Microcal, Northampton, 
MA, USA). The non-parametric Mann-Whitney U-test was used and a p-value < 0.05 considered statistically 
significant.
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